Abstract: The invention relates to an extruder apparatus for the extrusion of caoutchouc mixtures and plastics, having a gear extruder consisting of a housing in which a pair of gears that mesh with one another, and two intake rollers, are housed, and there is also provided in the apparatus two intake channels and one extrusion channel. It is the task of the invention, by simple means, and in a simple manner, to improve material intake and to better fill the tooth spaces with the material to be extruded, and by doing so, to reduce inclusions of air that are brought along as well. The invention resides in the fact that one pushes in the material to be processed, as far as possible into the tooth spaces of the gears by means of the intake rollers, which are arranged at a point at which the teeth of the gears constitute, together with the inner wall of the housing, an intake slot, and in so doing, one expels, at least in part, the air that is situated in the tooth spaces.

Abstract: An extrusion head having a stationary part fixed on an extrusion installation having a plurality of extrusion cylinders supplying an extrudate formed from several components. The stationary part has extrudate flow channels each in communication with a respective extrusion cylinder and a common extrusion die. Two pivotable outer parts pivotally hinged on the stationary part are selectively swingable individually between open and closed positions by respective piston-cylinder units. The two outer parts define an extrusion orifice for the die in their closed position. A pair of locking piston-cylinders provided with hammerhead piston rods hold the respective outer parts clamped against the stationary during an extrusion. Actuator piston-cylinder units selectively swing the piston rods of the locking piston-cylinder units clear of the outer parts for opening them for cleaning extrudate channels or for an extrusion die change.

Abstract: The invention relates to combinations of angiotensin-converting enzyme inhibitors with calcium antagonists, processes for their preparation and their use as medicaments.

Abstract: The invention relates to combinations of angiotensin-converting enzyme inhibitors with calcium antagonists, processes for their preparation and their use as medicaments.

Abstract: The invention relates to new comoounds having a cognition adjuvant action, to the use of ACE inhibitors as medicaments having a cognition adjuvant action, to agents containing them, and to the use thereof for the treatment and prophylaxis of cognitive dysfunctions.

Abstract: The present invention relates to compounds of the general formula I ##STR1## in which A denotes a radical from the group comprising S, SO, SO.sub.2, O, CO, CS or a direct bond,B denotes the radical of an amino acid andD denotes a CH.sub.2 group or a radical --NR.sup.7 --, where R.sup.7 can be hydrogen or a (C.sub.1 -C.sub.4)alkyl radical;and in which R.sup.1 to R.sup.4 are defined as indicated in the description, to a process for the preparation thereof, to agents containing these, and to the use thereof.

Abstract: A paint sludge is subjected to aerobic biodegradation with increased dry content of the resulting sludge and the latter is then subjected to anaerobic biological degradation. The effluent from the two biostages are sterilized by ozonization, UV-irradiation or peroxide addition. The sludge from the anaerobic biostage can be dried to an inert granulate and drying vapors are recycled to the aerobic biostage. The sterile liquid is returned to the wash water circulation of the painting plant.

Abstract: Enzyme-inhibiting urea derivatives of dipeptides, a process for the preparation thereof, agents containing these, and the use thereof.The present invention relates to compounds of the formula I ##STR1## in which A and B denote, indpendently of one another, an amino acid,X as desired can be absent or represents --O--, --S--, --CF.sub.2 --, --CO-- or --CHR.sup.8,p and q denote, independently of one another, 0, 1, 2, 3 or 4, andR.sup.1 to R.sup.4 are defined in the description, as well as the salts thereof.The invention furthermore relates to a process for the preparation of the compounds of the formula I and to the use thereof as medicines.

Abstract: New amino acid esters, a process for their preparation, medicaments containing them, and the use thereof The invention relates to amino acid esters of the formula I ##STR1## in which n is 1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 denote hydrogen or a defined radical, R.sup.4 together with R.sup.5 and the atoms carrying them form a heterocyclic ring system, to a process for their preparation, to agents containing them, and to the use thereof.

Abstract: The invention relates to combinations of angiotensin-converting enzyme inhibitors with calcium antagonists, processes for their preparation and their use as medicaments.

Abstract: The invention relates to compounds of the formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.4 represent optionally substituted aliphatic, alicyclic, alicyclic-aliphatic, aromatic, araliphatic, heteroaromatic or heteroaromatic-aliphatic radicals, with R.sup.2, if not already covered by the above-mentioned definitions, denoting the side-chain, which is protected if necessary, of a naturally occurring .alpha.-amino acid, R.sup.4 can additionally represent ##STR2## R.sup.3 denotes an optionally substituted aliphatic, alicyclic, aromatic or araliphatic radical, or R.sup.3 and R.sup.4 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system,agents containing these, and the use thereof as pharmaceuticals having a psychotropic action for the prophylaxis of disorders of the central nervous system, especially having a nootropic action for the treatment of cognitive dysfunctions.

Abstract: The present invention relates to compounds of the formula I ##STR1## in which R.sup.1 to R.sup.4 are defined in the description, processes for their preparation, their use for the treatment and prophylaxis of cognitive dysfunctions and pharmaceuticals containing them and processes for their preparation.

Abstract: The invention relates to amino acid esters of the formula ##STR1## in which n=1 or 2, R, R.sup.1, R.sup.2 and R.sup.3 denote hydrogen or a defined radical, R.sup.4 together with R.sup.5 and the atoms carrying them form a heterocyclic ring system, processes for their preparation, agents containing them and their use.

Abstract: The invention relates to amino acid esters of the formula I ##STR1## in which n is 2 and R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meaning indicated in the description, to a process and intermediates for the preparation thereof, to agents containing them, and the use thereof.

Abstract: Compounds with a psychotropic action, agents containing them, and the use thereof for the treatment and prophylaxis of disorders of the central nervous system.The invention relates to the use of angiotensin converting enzyme inhibitors as pharmaceuticals with a psychotropic, especially anxiolytic, action, to agents containing them, and to the use thereof for the treatment or prophylaxis of disorders of the central nervous system, especially of anxiety states.The invention also relates to new compounds of the formula ##STR1## in which R.sup.2 denotes hydrogen or ethyl, and R.sup.3 denotes n-octyl, to processes for the preparation thereof, to agents containing them, and to the use thereof as pharmaceuticals.

Abstract: Compounds I are described ##STR1## with R.sup.1 equal to (cyclo)alk(en)yl or ##STR2## R.sup.2 /R.sup.3 equal to phenyl or phenylalkyl, A equal to ##STR3## m equal to 2-4, and n equal to 1-4.Compounds I and their salts are calcium antagonists.

Abstract: A compound I ##STR1## in which R.sup.1 is cycloalkyl, alkenyl, cycloalkenyl, phenyl, ##STR2## whereJ, L, M, and E are methine or nitrogen and J', L', M', and E' are methylene, carbonyl or imino;R.sup.2 is phenyl or phenylalkyl;a is various amine radicals;m is 2, 3 or 4; andn is 1, 2, 3, or 4 is described; salts of these compounds I are also described. Compounds I and the salts are calcium antagonists.

Abstract: Derivatives of tetrahydroquinoline of the formula I ##STR1## and acid addition salts thereof, wherein n denotes 2, 3, 4, 5 or 6, R.sup.1 denotes, for example, alkyl, phenyl or pyridyl, R.sup.2 denotes the radical ##STR2## R.sup.3 and R.sup.4 independently of one another denote, for example, hydrogen, alkyl or cycloalkyl and R.sup.5 denotes, for example, hydrogen, alkyl or phenyl, have useful pharmacological properties.